Description
Olaparib is the salt name of the medication and it is marketed under the brand name Lynparza among others. It is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
In December 2014, olaparib was approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and by the Food and Drug Administration (FDA) in the United States.
OLAPARIB is a chemotherapy drug. It targets specific enzymes within cancer cells and stops the cancer cell from growing. This medicine is used to treat certain kinds of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Who is the CFA, distributor, and retailer for Lynparza (Olaparib) Tablets in India?
Aark Pharmaceuticals is an authorized distributor, CFA (Carry and Forward Agent), and retailer for Lynparza (Olaparib) Tablets in India. It is marketed by AstraZeneca. Aark claims to provide 100% authentic, cold-chain managed medicines. Aark supplies a wide range of AstraZeneca products, including advanced cancer treatments.
The company serves hospitals, clinics, and patients across India, including major cities like Bangalore, Surat, Kolkata, Indore, Nagpur, Patiala, Srinagar, Ahmedabad, Osmanabad, Mumbai, Pune, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Coimbatore, Kochi, Kollam, Agartala, Lucknow, Dehradun, Gairsain, Aizawal, Aurangabad, Barshi, Karungapally, Pondichery, Punjab, Delhi, New Delhi, Agra, Kanpur, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad, Wardha, Bhopal, Manipur, Mizoram, Sikkim, Tripura, Arunachal, Meghalaya, Nagaland, Pasighat, Cachar, Dibrugarh, Kamrup.
How much do Lynparza Tablets cost in Delhi, India?
Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals
Contact Person: Ms. Himanshi
Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016.
Do you offer any discounts?
Yes. Based on availability, prices may vary based on your prescribed treatment plan. Please ask for the best current price.
Prior to consuming any medications, including Olaparib Tablets, it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
List of available brand-name drugs in India for Olaparib Tablets
Branded Drugs for Olaparib Tablets: Lynparza | BDPARP | Brcarib | Parbraze | Ribaxa | BRACANAT | Obrenza
NEWS / UPDATES
- FDA approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based.
- FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer
- DCGI approved AstraZeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer
- Recommendations of the SEC (Oncology) made in its 18 th/24 meeting held on 10.09.2024 at
CDSCO HQ New Delhi: - DCGI orders withdrawal of cancer drug Olaparib for certain treatments
